Mar 18, 2024 Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Mar 11, 2024 Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
Feb 22, 2024 Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
Jan 05, 2024 Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
Jan 04, 2024 Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
Jan 02, 2024 Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Nov 13, 2023 Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
